Global Pharmacovigilance Market by Service Type (Adverse Drug Reaction (ADR) Monitoring, Risk Management, Data Management and Analysis, Regulatory Reporting, Others), by Source of Data (Clinical Trials, Post-Marketing Surveillance, Literature Review, Spontaneous Reporting, Others), by End-User (Pharmaceutical Companies, Contract Research Organizations (CROs), Regulatory Authorities, Healthcare Providers, Others); Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Pharmacovigilance Market was valued at USD 7.8 Billion in 2024-e and will surpass USD 14.4 Billion by 2030; growing at a CAGR of 10.7% during 2025 - 2030.

 The pharmacovigilance market plays a crucial role in ensuring the safety and efficacy of pharmaceutical products after they enter the market. This field involves monitoring the safety profile of drugs through the identification, assessment, and prevention of adverse drug reactions (ADRs). With the increasing complexity of drug development and regulatory scrutiny, pharmacovigilance has become an integral component of post-marketing surveillance. As the pharmaceutical industry focuses on improving patient safety and regulatory compliance, the demand for comprehensive pharmacovigilance services continues to grow globally.

Adverse Drug Reaction (ADR) Monitoring Leads the Market Due to Increasing Drug Safety Concerns

Adverse Drug Reaction (ADR) monitoring is the largest service type in the pharmacovigilance market, driven by the increasing focus on patient safety and the need to identify potential risks associated with drugs after they are approved for sale. ADR monitoring involves collecting, analyzing, and evaluating reports of adverse effects caused by drugs, allowing healthcare providers and regulators to take necessary actions, such as warning labels, dosage adjustments, or even drug recalls.

With the rising number of pharmaceutical products entering the market and the growing complexity of drug formulations, the demand for ADR monitoring services has intensified. Pharmaceutical companies, healthcare providers, and regulatory authorities are focusing on improving safety profiles through efficient ADR detection and reporting systems. This has made ADR monitoring a critical component of the pharmacovigilance process, further propelling the market growth.

Post-Marketing Surveillance is the Fastest Growing Data Source Due to Regulatory Mandates

Post-marketing surveillance is the fastest-growing data source in the pharmacovigilance market. After a drug is released to the market, continuous monitoring is essential to detect rare or long-term adverse effects that may not have been identified during clinical trials. Post-marketing surveillance provides crucial data on the real-world safety and efficacy of drugs, helping to ensure that any potential risks are promptly identified and mitigated.

Regulatory authorities across the globe, such as the FDA and EMA, have mandated post-marketing surveillance programs to monitor the safety of drugs once they are made available to the public. This regulatory push, combined with increasing consumer awareness, is driving the growth of post-marketing surveillance services. Pharmaceutical companies are investing in more robust surveillance systems to ensure compliance and maintain public trust in their products.

Pharmaceutical Companies Are the Largest End-User Due to Extensive Safety Monitoring Requirements

Pharmaceutical companies are the largest end-users in the pharmacovigilance market due to the extensive safety monitoring requirements mandated by regulatory authorities. These companies rely on pharmacovigilance services to collect data, manage adverse event reports, and ensure compliance with safety regulations. With increasing global regulatory scrutiny and the need to maintain a strong safety profile for drugs, pharmaceutical companies are investing heavily in pharmacovigilance to protect patient safety and avoid costly recalls or penalties.

The pharmaceutical industry's role in managing post-marketing drug safety is critical, and as the number of new drugs continues to rise, so too does the need for comprehensive pharmacovigilance systems to support ongoing safety monitoring and regulatory reporting.

North America Dominates the Market Due to Strong Regulatory Framework and Healthcare Infrastructure

North America is the largest market for pharmacovigilance services, driven by a strong regulatory framework, advanced healthcare infrastructure, and a high number of pharmaceutical companies operating in the region. The United States and Canada have well-established regulatory authorities, such as the FDA and Health Canada, which enforce strict pharmacovigilance guidelines to ensure drug safety and efficacy.

In addition to regulatory pressures, North American pharmaceutical companies are at the forefront of adopting advanced pharmacovigilance solutions, such as automated ADR monitoring systems and AI-powered data analysis tools. This has positioned North America as the dominant region in the global pharmacovigilance market, with significant investments in safety monitoring technologies and services.

Competitive Landscape and Key Players

The pharmacovigilance market is highly competitive, with key players such as Parexel International, Accenture, Covance, Syneos Health, and IQVIA leading the industry. These companies provide a range of pharmacovigilance services, including ADR monitoring, risk management, data analysis, and regulatory reporting, to help pharmaceutical companies comply with regulatory requirements and ensure drug safety.

With the increasing complexity of pharmacovigilance data and the growing use of technology, many of the leading players are investing in advanced solutions, such as cloud-based platforms, AI, and machine learning, to streamline data collection and analysis processes. Companies are also expanding their service offerings to cover the entire drug lifecycle, from pre-marketing safety assessments to post-marketing surveillance, to meet the evolving needs of the pharmaceutical industry.

Recent Developments:

• IQVIA Inc. announced the launch of a new pharmacovigilance platform to improve ADR reporting and risk assessment.
• F. Hoffmann-La Roche Ltd. expanded its global pharmacovigilance network to enhance drug safety and regulatory compliance.
• Parexel International Corporation entered into a partnership to enhance its pharmacovigilance services with advanced AI-powered analytics.
• Merck & Co., Inc. introduced a real-time pharmacovigilance dashboard for better monitoring of drug safety across regions.
• Johnson & Johnson Services, Inc. acquired a pharmacovigilance software company to strengthen its drug safety infrastructure.

List of Leading Companies:

• F. Hoffmann-La Roche Ltd.
• Novartis International AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Sanofi S.A.
• AbbVie Inc.
• Merck & Co., Inc.
• IQVIA Inc.
• Parexel International Corporation
• Celerion Inc.
• ICON plc
• Wipro Limited
• Covance Inc.

Report Scope: